Abstract: The human leukocyte antigen (HLA) system is an important immunologic barrier that must be considered for successful solid organ transplantation. Formation of donorspecific HLA antibodies in solid organ transplantation is an important cause of allograft injury and may contribute to recipient morbidity and mortality. Therapeutic plasma exchange is often requested to lower HLA antibody levels prior to or after transplantation and for management of HLA antibodies in the context of organ rejection. In this review, we summarize the current terminology, laboratory testing, and clinical significance of HLA sensitization in the solid organ transplant population. Furthermore, to illustrate applications of HLA testing in clinical practice, we summarize our own lung and kidney institutional protocols for managing HLA antibodies in the peri-transplant setting.
Solid organ transplantation is an important therapeutic option for a variety of end-stage diseases affecting the kidney, liver, lung, heart, and intestine. In the United States, approximately 30,000 organs are transplanted annually (1) (2) (3) (4) (5) (6) . One of the major immunological barriers to transplantation is the presence of preformed antibodies to the human leukocyte antigens (HLA). Development of HLA antibodies prior to or after transplantation (pre and post-transplant HLA sensitization, respectively) is associated with graft dysfunction, transplant rejection, and poor overall survival (7) .
The management of patients with pre-and posttransplant sensitization involves multidisciplinary teams and often includes the apheresis practitioner, who is frequently asked to provide therapeutic plasma exchange (TPE) in the peri-transplant setting. In this paper, we review the terminology and laboratory assays for detecting HLA antibodies in patients undergoing solid organ transplantation. We also summarize a peri-transplant HLA testing protocol used by the lung and kidney transplant programs at Duke University Medical Center to illustrate an algorithm-based strategy for management of HLA sensitized patients and demonstrate important scenarios in which TPE may be requested.
HLA system, an immunologic barrier to transplantation
Unlike the ABO blood group system, which is limited to three allelic forms (A, B and O), the HLA system is a far more complex system of cell-surface antigens that distinguish "self" from "non-self." The HLA system is encoded by the human major histocompatibility complex (MHC), a highly polymorphic region on the short arm of human chromosome 6. The gene products encoded by the MHC complex are expressed as co-dominant alleles and account for the marked immunologic diversity among individual humans (8) . Presently, the database of HLA alleles cites 13 023 distinct HLA alleles in the human genome (9) . In the context of organ transplantation, differences in donor and recipient HLA expression provide a continuous source of antigenic stimulation to the immune system.
The physiologic role of the HLA system is to continually present peptides to T-cells, thereby allowing for tolerance of cells expressing self antigens and the elimination of cells expressing non-self antigens. To render this specificity, the MHC encodes two classes of antigens -class I and class II -each expressing three distinct antigenic clusters (8) . Class I antigens include the HLA-A, -B, and -C antigenic clusters while class II antigens include the HLA-DR, -DQ, and -DP antigenic clusters. HLA class I proteins are expressed on nucleated cells, platelets, and sometimes (in about 15% of the population) on red cells (10, 11) . MHC class II proteins, however, are restricted to expression on specialized antigen presenting cells such as B-cells, macrophages, and dendritic cells. Under conditions of inflammatory stress, MHC class II expression can be upregulated on a large variety of cells that do not typically present class II antigens (12) (13) (14) (15) . Antigen presenting cells have the capacity to process self and non-self antigens and present processed antigens to T-cells. In solid organ transplantation, the HLA proteins on donor organs and donor cells are processed as foreign antigen.
Terminology and risk factors for sensitization
HLA sensitization to donor antigens can occur prior to or after transplantation. Pre-transplant sensitization has been found in up to 30% kidney (16, 17) , 18% heart (18, 19) , 29% lung (20, 21) , and 20% liver transplant candidates (22) . Post-transplant, donor specific sensitization occurs in up to 20% kidney, 19% liver, 23% heart, and 14% lung transplants (23) . Among non-sensitized patients, an estimated 14% develop de novo antibodies after transplantation.
Interestingly, pre-transplant sensitization does not necessarily predict posttransplant antibody formation. Indeed, an estimated 47% of pre-sensitized renal patients were reported to become seronegative after transplantation, perhaps due to tolerance induction and/or effects of chronic immunosuppression (23) .
Risk factors for HLA sensitization include prior transplantation, blood product transfusion, pregnancy, and ventricular assist device use (24, 25) . Of these risk factors, the strongest is a history of prior transplantation. In a study assessing class II sensitization among various solid organ candidates for re-transplantation, 43 of 75 patients (57%) were sensitized (26) . Other studies have documented post-transplant HLA seroconversion in 50-76% of previously transplanted patients (27, 28) . In a single report, HLA-specific allosensitization was thought to be transferred to the recipient from a highly sensitized organ donor (29) . In individuals without a history of transplantation, depending on whether or not leukoreduced products are used, transfusion can account for 20 to 33% of sensitizing events (27, 30) . Among transfused patients, females have higher rates of sensitization (33-60%) than males (17-34%), (27, 31) with an incidence of up to 71% among women with prior pregnancy (27) .
HLA antibodies are termed donor-specific (DSA) if they recognize HLA proteins found in the allograft, or non-donor-specific (non-DSA) if the HLA antigens are not present on the transplanted organ. In the literature, non-DSA are also referred to as "third party" antibodies and can be present before a transplant or appear de novo after transplantation (32) . In several studies, post-transplant DSA may be associated with HLA-DRβ1 or medication nonadherence (33) and have been associated with higher rates of chronic rejection (34) or decreased overall survival (35, 36) as compared to third-party antibodies. Other serologic characteristics of HLA antibodies, such as antibodies to class I or class II antigens, have also been studied with respect to outcomes of acute or chronic rejection. Some studies have shown that HLA class I antibodies are more likely to be associated with acute rejection (37) while HLA class II antibodies are more likely to cause chronic rejection (35, 38, 39) ; however, this relationship of HLA class to rejection type has not been confirmed in other studies (40) . Furthermore, Class II HLA epitope matching, rather than antigen matching, may decrease development of DSA (41) .
Some DSA use complement fixation as their primary mechanism of antibody-mediated allograft damage. Complement-fixing DSA may be important mediators of allograft injury (42 (42) . Furthermore, in renal transplantation, C1q positive DSA are considered to be an independent predictor of AMR (45) .
Detection of HLA antibodies HLA antibodies are detected through a variety of immunologic assays. The Panel Reactive Antibody (PRA) score is a broad parameter for determining the degree of HLA sensitization in an individual. The PRA score is calculated using a panel of HLA antigens representative of the HLA distribution in the donor population (46) . Depending on the technique used, a PRA score will typically correspond to the percentage of antibodies reacting to a panel of microtiter plate-or latex bead-coated lymphocyte antigens. With the methodological variability in calculating PRA among various testing centers and increase in reliance on solid phase immunoassays for HLA testing, the United Network for Organ Sharing (UNOS) Histocompatibility Committee developed the calculated PRA score (cPRA). The cPRA is based on HLA specificities deemed unacceptable for an individual sensitized patient and calculates the frequency of these antigens based on a historic donor population (47) (48) (49) . Thus, a cPRA represents the percentage of donors who are expected to have unacceptable HLA antigens to which the transplant candidate is sensitized (48) .
HLA antibodies can be detected either through cell-based assays or solid phase immunoassays The term "solid phase" designates the wells or the solid polystyrene or latex beads on which the target HLA proteins are coated (31) . Historically, cellbased assays were developed first; however, due to improvements in the sensitivity and specificity of immunologic assays in the last 15 years, solid phase assays are more commonly used (48).
Cell-based assays for detection of HLA antibodies
The complement dependent cytotoxicity assay (CDC) is a historic cell-based assay that assesses the presence of complement-fixing HLA antibodies in patient serum. Serum is mixed with a panel of local blood donor or commercially-available B-and Tlymphocytes (50) . If present in the serum, complement dependent HLA antibodies will bind to HLA proteins on lymphocytes, initiate complement-mediated injury, and result in lymphocyte death (31, 51) . Percent lymphocyte death is assessed by microscopy. If lymphocyte deaths are observed, then it is a positive result, with the percentage of lymphocyte deaths expressed as a percentage or %PRA. Assay positivity is generally followed by immunoassays to determine the fine antigen-specificities of HLA antibodies (24) .
Until 2000, CDC was used routinely to predict humoral hyperacute rejection. This predictive capability was first shown by Patel and Terasaki in their 1969 landmark study (52) in which 80% of grafts showing a positive CDC cross match failed immediately as compared to only 4% of those with a negative cross match. However, CDC's poor reproducibility, variability, inability to provide HLA specificity, and inability to detect non-complement fixing HLA antibodies led to its eventual decline (50, (53) (54) (55) . Presently, its usefulness in identifying antibodies with functional properties of complement activation allows CDC to remain in use as a supplementary technique.
The solid phase immunoassays (SPI) for detection of HLA antibodies
Solid-phase immunoassays have largely been developed to overcome the limitations of cell-based assays. Their technical advantages, which enable automation and rapid turnaround, and their ability to identify both complement and non-complement dependent antibodies, make them a preferred method. Solid phase matrix (plates or beads) is coated with single or multiple HLA antigens. Antibodies to these antigens are detected by means of enzyme linked immunosorbent assay (ELISA), flow cytometer, or Luminex (Luminex, Austin, TX, USA) (31) .
ELISA based detection of HLA antibodies
The first solid phase immunoassays developed for detection of HLA antibodies were based on ELISA methodology. To detect HLA antibodies in this assay, HLA antigens coated on a microtiter plate are incubated with patients' serum (56) . Various studies show that the sensitivity of ELISA for HLA antibody-detection is higher than CDC (97% vs 78%), (56, 57) . Nevertheless, ELISA assays are now largely supplanted by antigen-bead assays, which use flow cytometry and/or laser-based multiplex technology (Luminex). These latter assays are not only more sensitive, but also allow for rapid analysis of multiple analytes.
Flow cytometry detection of HLA antibodies
As a technique, flow cytometry has broad applications in transplant immunology because of its ability to identify antibodies to HLA antigens from a pool of donors; define HLA specificity; and HLA Sensitization in Organ Transplant 3
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perform a crossmatch (31, 58, 59 ). Example of a FlowPRA result is shown in Figure 1 .
HLA antibody detection. For HLA antibody detection, patient serum is incubated with purified HLA antigen-coated latex beads. Bound antibodies are detected using fluorescent tags (58) . The number of beads with bound antibodies relative to the number tested is expressed as the %PRA.
Definition of HLA specificity. To determine the specificity of antibodies, a patient's serum can be further interrogated using the same technique with single HLA antigen-coated beads. Because of the higher concentration of a given antigen on coated beads, the single antigen technique appears to have a higher sensitivity than the pooled antigen assay described above (57) .
Virtual crossmatch. Identifying the specificities of HLA antibodies is also critical for virtual crossmatch (VXM). In VXM, antibodies in the transplant recipient are matched against the HLA antigen profile of a potential donor (60).
Prospective crossmatch. Flow cytometric techniques are also used for performing a "true" prospective crossmatch (PXM) (61) . For the prospective crossmatch, T-and/or B-lymphocytes from donor blood, lymph nodes or spleen are incubated with the recipient's serum and bound antibodies are detected by flow cytometry. The main limitation of flow cytometry-based assays is in the lack of standardization. Differences between flow cytometers, fluorochromes, and secondary antibodies have made it difficult for centers to validate thresholds for positivity (54, 62) . Additionally, flow cytometry-based assays can be difficult to interpret and determine the clinical significance of the identified antibodies.
Luminex-based detection of HLA antibodies
The Luminex system is a multiplex bead-based platform for detection of multiple analytes using laser excitation and light emission of uniquely colored florescent beads. Each distinctively colored bead is coated with a single HLA antigen and incubated with a patient's serum (63) . Bound antibodies are detected with a fluorescently labeled antibody to human IgG, using a dual laser to identify the bound antibody as well as the HLA antigen coated bead (63, 64) . Additionally, the intensity of the mean fluorescent signal (MFI) is often considered a surrogate measure of the level of HLA antibody (63, 65, 66) .
The strengths of Luminex based immunoassays are that they are non-cell based; allow a clear distinction between HLA class I and II positivity; enable VXM; provide semi-quantitative results; and offer rapid turnaround. Nevertheless, Luminex internet-based transplant information database, UNet. For cPRA ≥80%, any antigens likely to result in positive crossmatch (XM) are also listed as unacceptable in UNet. The gray dashed lines represent the pathway for some candidates with a cPRA ≥80 who are considered for a therapeutic plasma exchange (TPE)-based desensitization protocol. Prior to and after desensitization, FlowPRA, LSA, and dilution test are performed. Changes in cPRA and MFI of the antibodies will be monitored and used to determine the success of desensitization. (B) At transplant, A virtual crossmatch (VXM) is performed. If VXM is positive for a non-local deceased donor, the donor will be declined. If VXM is positive for a local donor, the transplant is put on hold pending results of the prospective crossmatch (XM). If the prospective XM is positive, then no transplant will occur. If, however, the initial VXM is negative, then we proceed with the transplant while a retrospective XM is in process. If the retrospective XM comes back negative, then the patient is maintained on a standard post-transplant monitoring protocol.
If the retrospective XM unexpectedly comes back positive, then, the patient will be treated with a TPE-based protocol. *For patients with a negative XM, TPE is considered if there is evidence or high concern for early allograft injury. [Color figure can be viewed at wileyonlinelibrary. com]
HLA Sensitization in Organ Transplant 5
demonstrates high technical variation with differences in MFI values as high as 20% (67) . Additionally, definition of negative and positive thresholds vary widely among transplant centers (64, 68) . Furthermore, Luminex assay is not quantitative (67) . An example of an HLA class II antibody Luminex single antigen bead assay result is shown in Figure 2 .
Virtual crossmatch in transplantation
Both flow cytometry and Luminex-based immunoassays allow for determination of VXM. In VXM, the specificities of HLA antibodies detected in the transplant recipient are matched against the HLA antigen profile of a potential donor. Because donor HLA antigens can be matched against recipient HLA antibodies, VXM enlarges the catchment area for organ procurement and reduces transplant wait times (69) .
Studies indicate that patients transplanted using VXM have similar long-term outcomes as those transplanted using a traditional prospective cell-based crossmatch (PXM) using donor and recipient samples. Whether PXM or VXM was performed, similar outcomes in 3-year overall survival were seen in both non-sensitized (84.6 vs. 77.2%) and sensitized (76.9 vs. 77.4) patients (P = 0.49) (70) . Additionally, no differences in acute cellular and antibody-mediated rejection were observed. However, average number of days on the transplant waiting list was statisticallysignificantly decreased in the VXM era (129 ± 246 PXM vs. 59 ± 78 days VXM P = 0.018). This study and others have shown that outcomes for PXM and VXM are comparable and significantly decrease both transplant wait times and attributable mortality (20, 69, 71) .
Duke Medicine HLA testing protocols for solid organ transplantation
At Duke University Medical Center, we have active programs in kidney, liver, heart, lung, and intestine transplant. In general, our primary methods for HLA antibody screening and identification are flow cytometry antibody screening, FlowPRA (One Lambda, Canoga Park, CA, USA) and Luminex single antigen bead array assay (LSA, One Figure 3 and for our renal transplant program in Figure 4 .
Use of the algorithm in Figure 3 may be modified on a case-by-case basis. For instance, in lung transplant patients who have cPRA >80%, we consider using a 1:16 dilution as well as evaluation of the MFI and density of the HLA antigen on the bead to determine the strength and, possibly, the clinical significance of the antibody. If the antibody is a weaker or less commonly expressed antibody, which may not have clinical significance, we will consider transplantation across a positive crossmatch with the aid of a TPE-based protocol (73) .
Utility of apheresis in HLA desensitization protocols
HLA antibody testing is critical for both pretransplant assessment of permissible donors and peri-transplant management of the recipient. Clinicians caring for the transplant recipient rely heavily on the information provided by the HLA laboratory to make clinical decisions. However, clinical decision-making is fraught with the limitations of the testing and complexity of the results and their interpretation, which can make it Immunoadsorption is not available in the United States. *Low risk: Positive donor specific antibodies (DSA) with negative B and/or T cell flow cross match (FXM) and negative lymphocytotoxicity crossmatch assay (CDCXM), Intermediate risk: +DSA, +FXM, and negative CDC XM, and High risk: +DSA, +FXM, and + CDC XM or repeat transplant with human leukocyte antigen (HLA) mismatch HLA. **Separate follow up times reported for group treated with IA alone and IA in tandem with dialysis. ***Low risk: +Luminex XM, ÀFXM, ÀCDCXM; Moderate risk: +Luminex XM, +FXM, ÀCDC XM; High risk: +Luminex, +FXM, + CDCXMABOi, ABO incompatible; DSA, Donor specific antibodies. R, Rituximab. MCS, mean channel score; HLAi, HLA incompatible; TPE, Therapeutic plasma exchange; ATG, anti-thymocyte globulin; IVIG, intravenous immunoglobulin; QOD, every other day; POD, post-operative day.
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challenging to determine which, if any, of the identified antibodies could be clinically significant. Therefore, when in doubt, transplant physicians may consider TPE in the management of the transplant recipient and rely on the apheresis practitioner to guide use of TPE in this increasingly complex patient population. TPE is frequently used in desensitization protocols. Although best studied in renal transplantation, desensitization protocols are also being used prior to heart and lung transplantation to decrease the burden of HLA antibodies and facilitate transplantation across a high PRA (74) (75) (76) (77) (78) (79) (80) . Outcomes of non-TPE and TPE-based desensitization protocols have previously been summarized in outstanding reviews (81, 82) Recent studies of desensitization protocols that utilize TPE or immunoadsorption (IA) are outlined in the Table 1 .
With limited data available to guide therapy in some solid organ indications such as heart, lung, intestine, and pancreas transplant, in its guidelines, the American Society for Apheresis (ASFA), recognizes the importance of individualized decision-making in the care of the transplant recipient (83) . Therefore, to be successful in caring for the patient and preserving the functionality of the transplanted organ, there must be bi-directional dialogue between the transplant and apheresis teams to determine the right apheresis prescription and outline objective measures for determining failure or success of TPE.
CONCLUSION
The human leukocyte antigen antigenic system is a critical determinant of transplant outcome. Sensitive immunoassays have resulted in improved detection of human leukocyte antigen antibodies and enabled virtual crossmatch as well as correlation with clinical outcomes. As apheresis is often used in the management of human leukocyte antigen sensitized patients, practitioners should be knowledgeable about human leukocyte antigen testing, its limitations, and strengths.
